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Groningen, The Netherlands; 2Brain Physiology Research Unit, Semmelweis University, Budapest, Hungary; and 3Tokyo
Metropolitan Institute of Gerontology, Tokyo, Japan
Pituitary tumors are often detected only after death or at late stages
of the disease when they are macroadenomas with a low surgical
cure rate. Spontaneous pituitary tumors occur in rats over 1 y of age.
In an ongoing study of changes in s-1 agonist binding related to
aging, several of our rats developed such tumors. The aim of the
current study was to assess the kinetics of 11C-SA4503 (11C-labeled
1-[2-(3,4-dimethoxyphenthyl)]-4-(3-phenylpropyl)-piperazine dihy-
drochloride) in tumor and brain and to evaluate the utility of this
tracer in the detection of pituitary tumors. Methods: Small-animal
PET scans of the brain region of male Wistar Hannover rats (age,
18–32 mo) were acquired using the s-1 agonist tracer 11C-SA4503.
The time-dependent uptake of 11C in the entire brain, tumor or normal
pituitary, and thyroid was measured. A 2-tissue-compartment model
was fitted to the PET data, using metabolite-corrected plasma radio-
activity as the input function. Results: Pituitary tumors showed up
as bright hot spots in the scans. The total distribution volume (VT) of
the tracer was significantly higher in the tumor than in the normal
pituitary. Surprisingly, a higher VT was also seen in the brain and
thyroid tissue of animals with pituitary tumors than in healthy rats.
The increase inVT in the brain and thyroidwas not related to a change
in nondisplaceable binding potential (BPND) but rather to an increase
in the partition coefficient (K1/k2) of 11C-SA4503. The increase in VT in
the tumor on the other hand was accompanied by a significant in-
crease in BPND. Western blotting analysis indicated that pituitary
tumors overexpressed s-1 receptors. Conclusion: The overexpres-
sion of s-1 receptors in spontaneous pituitary tumors is detected as
an increase in uptake andBPND of 11C-SA4503. Therefore, this tracer
mayhave promise for the detection of pituitary adenomas, usingPET.
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tumor; kinetic analysis; small-animal PET
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Pituitary tumors (adenomas of the pituitary gland) are among
the 5 most common intracranial neoplasms (1,2). Pituitary adeno-
mas grow slowly and metastasize rarely (3). Despite their benign
nature, they can cause significant morbidity (4). For example,
pituitary tumors can lead to Cushing syndrome, pituitary hyperthy-
roidism, acromegaly, Nelson syndrome, or impotence (5,6). Un-
fortunately, pituitary tumors are difficult to diagnose and often
remain undetected until postmortem examination or during late-
stage disease (7,8). At late stages, most pituitary tumors will be
macroadenomas with a low surgical cure rate (3). Diagnostic prob-
lems arise from the fact that they can manifest by varying symp-
toms. Functioning tumors hypersecrete various hormones (e.g.,
prolactin, thyroid-stimulating hormone, and growth hormone),
and nonfunctioning tumors (nonsecreting) grow usually unde-
tected until they compress surrounding structures (e.g., optic
nerves) or prevent normal functioning of the pituitary gland (9).
In addition, large pituitary tumors occasionally can cause fatal
damage to the brain due to a sustained increase in intracranial
pressure (10).
Because hormonal or symptom examination gives a rather poor
differential diagnosis, current diagnostic methods include imaging
techniques such as CT or MR imaging. CT and MR imaging allow
avoidance of biopsies and significantly improve pituitary tumor
localization (9,11,12). However, CT and MR imaging cannot dis-
tinguish between tumor and scar tissue or monitor biochemical
and functional aspects of the tumor.
There is no tracer of first choice for pituitary tumor imaging
using nuclear medicine (4), although such lesions have been visu-
alized with, for example, 18F-FDG, radioactively labeled somato-
statin analogs such as 111In-pentetreotide, and dopamine D2
receptor–targeting radiopharmaceuticals such as 18F-fluoroethyl-
spiperone (1,4,7). The widespread use of 18F-FDG in PET imaging
over the last 2 decades increased the detection of incidentalomas of
the pituitary gland (7,13). However, pituitary tumors are slow-grow-
ing and highly differentiated, making 18F-FDG unsuitable for their
imaging (4). Furthermore, 18F-FDG poorly distinguishes between
nonneoplastic and neoplastic lesions, benign lesions and malignant
lesions, and inflammation, and accumulation of this tracer in the
pituitary gives an ambiguous interpretation (7,13–15). Huyn et al.
showed that only 40.8% of the patients with focal pituitary 18F-FDG
accumulation presented with pathologic lesions (7). On the other
hand, somatostatin receptor and dopamine D2 receptor–targeting
radiopharmaceuticals have only limited clinical usefulness, because
expression of these receptors depends on the hormones that the
pituitary tumor secretes (e.g., higher expression of somatostatin re-
ceptors in tumors producing growth hormone or thyroid-stimulating
hormone, and higher expression of dopamine D2 receptors in non-
secretive tumors) (4,12,16).
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Tumor cells frequently overexpress s-receptors. Sigma recep-
tors are unique transmembrane proteins classified into 2 subtypes,
s-1 and s-2 (17). s-1 receptors have been studied in more detail
than s-2 receptors since the s-1 but not the s-2 gene has been
sequenced and cloned (18). s-1 receptors were shown to be an
intraorganelle signaling and cell survival modulator at the endo-
plasmic reticulum–mitochondria junctions (19). The s-2 subtype
was recently identified as the progesterone receptor membrane
component 1 (20). s-1 receptors are expressed at rather high
densities in the brain and pituitary gland (21). However, the
presence of s-1 receptors in pituitary tumors has not yet been
examined.
11C-SA4503 (11C-labeled 1-[2-(3,4-dimethoxyphenthyl)]-4-(3-
phenylpropyl)-piperazine dihydrochloride) is a ligand with high
affinity for s-1 (inhibitory concentration of 50%, 17.4 nM) and
lower affinity for s-2 receptors (1,784 nM) and is commonly used
for PET (17). We have previously reported that small-animal PET
with 11C-SA4503 shows high tracer accumulation in the mamma-
lian brain (22). 11C-SA4503 was already tested in healthy volun-
teers and in patients with Alzheimer disease (23) or Parkinson
disease (17,24). Furthermore, small-animal PETwith 11C-SA4503
in rats successfully detected subcutaneously grown C6 gliomas,
had 10-fold C6 tumor selectivity over turpentine-induced sterile
inflammation, and after systemic doxorubicin treatment showed
an early decrease in tumor uptake that corresponded to a loss of
s-1 receptors from the tumors (25,26).
In the current study, we examined if spontaneously developed
pituitary tumors in aged rats can be detected and distinguished
from the normal pituitary by small-animal PET imaging with 11C-
SA4503. Also, we performed kinetic analysis of tracer uptake in
the brain, pituitary tumors, and thyroid gland, using a 2-tissue-
compartment model fit to assess changes in partition coefficient
(K1/k2), nondisplaceable binding potential (BPND), and total dis-
tribution volume (VT). Finally, the impact of a pituitary tumor on
uptake of 11C-SA4503 in peripheral organs was examined, since
a pituitary tumor may affect the vascular properties and perfusion
of other tissues because of altered hormone levels.
MATERIALS AND METHODS
11C-SA503 Synthesis
The radioligand 11C-SA4503 was prepared by reaction of
11C-methyl iodide with 1-[2-(4-hydroxy-3-methoxy-penthyl)]-4-(3-
phenylpropyl)piperazine dihydrochloride (4-O-demethyl SA4503),
according to a published method (27). The decay-corrected radio-
chemical yield was about 24%, the specific radioactivity was greater
than 100 TBq/mmol at the moment of injection, and radiochemical
purity was greater than 98%. The 11C-SA4503 solution had a pH of
6.0 to 7.0.
Animal Model
Experiments were performed on male Wistar Hannover rats aged
18–32 mo. The animals were either purchased from Harlan or ac-
quired from Semmelweis University. It was previously reported that
more than 37% of male Wistar Hannover rats older than 1 y may
develop pituitary tumors (28). Additional pituitary tumors and normal
pituitary tissue for Western blotting were obtained from rats of similar
ages from Semmelweis University. The rats were housed in polycar-
bonate cages on a layer of wood shavings in a room with constant
temperature (21C 6 2C) and a fixed 12-h light–dark regime (light
phase from 7:00 AM to 7:00 PM). Food (standard laboratory chow,
RMH-B; Hope Farms) and water were available ad libitum. After
arrival, the rats were acclimatized for at least 7 d. Experiments were
performed by licensed investigators in compliance with the Law on
Animal Experiments in The Netherlands. The protocol was approved
by the Committee on Animal Ethics of the University of Groningen.
TABLE 1
Biodistribution of 11C-SA4503 in Pituitary and Tumor
Parameter Normal pituitary (n 5 5) Pituitary tumor (n 5 6) P
SUV 3.28 6 0.47 10.28 6 2.10 ,0.05
Tissue-to-brain ratio 2.90 6 0.61 5.70 6 0.77 ,0.05
Tissue-to-plasma ratio 17.29 6 1.72 101.1 6 19.42 ,0.01
Two rats that had large necrotic tumors were not included in this analysis.
Data are expressed as mean 6 SEM.
FIGURE 1. 11C-SA4503 small-animal PET images of healthy aged
rat (A) and aged rat with spontaneous pituitary tumor weighing 17
mg (B). Solid arrows indicate healthy pituitary or pituitary tumor;
dashed arrows indicate position of thyroid gland. COR 5 coronal;
SAG 5 sagittal view; TRANS 5 transverse.
1378 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 54 • No. 8 • August 2013
Animals were assigned to the healthy control (n5 8) or tumor-bearing
group (n 5 5) after autopsy.
Arterial Blood Sampling
Before PET scanning, an arterial cannula was placed in each rat for
blood sampling and determination of the time course of radioactivity
in plasma. For this purpose, the rats were anesthetized with isoflurane
inmedicinal air (5% for induction and 2% formaintenance). An incision
was made parallel to the femoral artery. The femoral artery was
separated from the femoral vein and temporarily ligated to prevent
leakage of blood. A small incision was made in the artery, and a cannula
was inserted (0.8-mm outer diameter, 0.4-mm inner diameter). The
cannula was secured to the artery with a suture and attached to a syringe
filled with heparinized saline.
From each rat, 15 arterial blood samples (0.1–0.15 mL) were col-
lected at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2.0, 3, 5, 7.5, 10, 15, 30, 60, and
90 min after 11C-SA4503 injection and the start of the small-animal
PET scan. Plasma was obtained from the blood by centrifugation
(5 min in an Eppendorf-type centrifuge at 13,000 rpm). Radioactivity
in plasma samples was determined using a calibrated g-counter (Com-
puGamma CS 1282; LKB-Wallac). Plasma data were corrected for
radioactive metabolites on the basis of the age of the rat.
In a separate group of animals, larger volumes of blood ranging
from 0.4 to 1.6 mL were collected at 5, 10, 20, 40, and 60 min, and
a metabolite analysis was performed using a method similar to one
previously published for 11C-SA4503 (29). Briefly, plasma was
obtained by centrifugation (2 min in an Eppendorf-type centrifuge at
13,000 rpm) and deproteinized using one third the volume of 20%
trichloroacetic acid in acetonitrile. The mixture was centrifuged for
2 min at 13,000 rpm, and the supernatant was injected in a reversed-
phase high-performance liquid chromatography system to separate
the parent tracer and metabolites. A Micro-
Bondapak C18 (7.8 · 300 mm) column and
a mobile phase consisting of a mixture of ace-
tonitrile and 50 mM sodium acetate buffer (pH
7.2; 1/1, v/v) at a flow rate of 3 mL/min were
used. The eluatewas collected in 30-s fractions
for 15 min, and radioactivity in the samples
was measured using a g-counter.
PET Scan
Two rats were scanned simultaneously in
each scan session, using a small-animal PET
camera (microPET Focus 220; Siemens/Con-
corde). They were placed in the camera in
transaxial position with their heads and necks
in the field of view. First, a transmission scan
of 515 s with a 57Co point source was obtained
for attenuation and scatter correction of
511-keV photons by tissue. Subsequently, the
first rat was injected through the penile
vein with 11C-SA4503 (316 16MBq, volume
, 1 mL). The emission scan was started with
tracer injection of the first rat, and the second
animal was injected a fewminutes later. A list-
mode protocol was used with a 90-min acqui-
sition time (analysis performed for the first
74 min from tracer injection). Reconstructions
were performed using microPET Manager
2.3.3.6 (Siemens). The list-mode data of the
emission scans were reframed into a dynamic
sequence of 8 · 30 s, 3 · 60 s, 2 · 120 s, 2 · 180
s, 3 · 300 s, 3 · 600 s, 1 · 720 s, 1 · 960 s
frames. The data were reconstructed per time
frame using an iterative algorithm (2-dimensional ordered-subsets ex-
pectation maximization with Fourier rebinning, 4 iterations, and 16
subsets). The final datasets consisted of 95 slices with a slice thickness
of 0.8 mm and an in-plane image matrix of 128 · 128 pixels. Voxel size
was 0.5 · 0.5 · 0.8 mm. The linear resolution at the center of the field of
viewwas about 1.5mm.Datasets were fully corrected for decay, random
coincidences, scatter, and attenuation.
PET Data Analysis
The images obtained from the scan were coregistered with an MR
imaging template (30) for drawing the 3-dimensional regions of in-
terest over the whole brain and healthy pituitary. Regions of interest
were also drawn over the thyroid and pituitary tumor using Inveon
Research Workplace software (Siemens). Time–activity curves were
calculated for each of these regions. Tracer uptake was expressed as
a PET standardized uptake value (SUV), assuming a specific gravity
of 1 g/cm3 for brain tissue and blood plasma. The parameter SUV is
defined as [tissue activity concentration (MBq/g) · animal body
weight (g)/injected dose (MBq)].
Kinetic analysis was performed by fitting a standard 4-parameter,
2-tissue-compartment model to the dynamic PET data, using metab-
olite-corrected plasma radioactivity from arterial blood samples as the
input function. The 2-tissue-compartment model was described pre-
viously (31); its parameters are rate constant for transport from arterial
plasma to tissue (K1), tissue to arterial plasma (k2), free compartment
to bound compartment in tissue (k3), and bound compartment to free
compartment in tissue (k4).When plasma datawere not available, a pop-
ulation average corrected for injected dose and weight of individual
animal was used as input. Software routines for Matlab 7 (The Math-
Works), written by Dr. Antoon T.M. Willemsen (University Medical
Center Groningen), were used for curve fitting. The blood volume was
FIGURE 2. Time–activity curves of 11C-SA4503 in plasma of normal (n 5 5) and tumor-
bearing (n 5 4) rats (A), normal pituitary (n 5 7) and pituitary tumors (n 5 5) (B), brain of
normal (n 5 7) and tumor-bearing (n 5 5) rats, (C), and thyroid of normal (n 5 7) and tumor-
bearing rats (n 5 5) (D). Data are expressed as mean 6 SEM; differences in area under
curve were tested with unpaired 2-tailed t test.
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fixed at 0.036, and the rate constants K1, k2, k3, and k4 were esti-
mated from the curve fit. The partition coefficient was calculated as
K1/k2, BPND was calculated as k3/k4, and VT was calculated as K1/k2
· (11 k3/k4).
Ex Vivo Biodistribution
After the scanning period, the animals were terminated by
extirpation of the heart. Blood was immediately collected, and plasma
and a cell fraction were separated by a short period of centrifugation
(5 min at 1,000g). Several tissues (Table 1) were excised. All tissue
samples were weighed. Radioactivity in tissue samples and in a sample
of the injected tracer solution (infusate) was measured using a g-
counter with automatic decay correction. The data are presented as
SUV. Tissue-to-plasma and pituitary- or tumor-to-brain concentration
ratios of radioactivity were calculated.
Western Blotting
A portion of the pituitary tumors (n 5 5) and the entire pituitary of
control animals (n 5 5) were homogenized in lysis buffer containing
137 mM NaCl, 20 mM Tris-HCl (pH 8.0), 2% Nonidet P-40 (Shell
Chemicals), 10% glycerol, and protease inhibitors. Total protein was
used for analysis rather than a plasma membrane fraction, since
most s-1 receptors are known to be intracellular and the intracellular
receptors are functionally important (17,19,21). Moreover, our ligand
11C-SA4503 visualizes the entire s-1 recep-
tor population because of its lipophilicity.
The homogenate was sonicated for 30 s in
a cold pack. Lysates were centrifuged for
15 min at 15,300g at 4C. Supernatants were
collected and stored at 220C until use. The
concentration of protein was determined with
a Bradford assay. Twenty micrograms of pro-
tein were electrophoresed on 8%–12% (v/v)
sodium dodecyl sulfate polyacrylamide gels.
Proteins were electrotransferred onto polyvi-
nylidene difluoride membranes (Amersham).
The nonspecific binding of immunoproteins
was blocked with 5% nonfat dry milk for 2
h at room temperature. After blocking, the
membrane was incubated with primary anti-
bodies overnight at 4C. The primary anti-
body recognizing s-1 receptors was
ab89655, an anti-Sig-1R antibody purchased
from AbCam. The membrane was rinsed in
Tris-buffered saline containing 0.1% polysor-
bate 20 followed by 1 h of incubation with
horseradish peroxidase–conjugated second-
ary antibody at room temperature. After in-
cubation, the membranes were repeatedly
washed in this same buffer and incubated
with an enhanced chemiluminescence reagent
(ECL Plus, RPN 2132; Amersham). The pro-
tein bands were visualized on x-ray films.
The optical density of the protein bands was
quantified using ImageJ (National Institutes
of Health) and standardized to b-actin
(1:2,000, SC-47778; Santa Cruz Biotechnol-
ogy).
Statistics
All results are expressed as mean 6 SEM.
Differences between groups were examined
by unpaired 2-tailed t testing or 2-way
ANOVA, followed by a post hoc Bonferroni
test, when applicable. A P value of less than
0.05 was considered statistically significant. Correlations were
assessed using the Pearson correlation coefficient (r) and considered
strong when r2 was at least 0.7 and significant when P was less than
0.05.
RESULTS
Tumor Visualization on PET Images
Spontaneous pituitary tumors developed in 38% of the aged
rats. These tumors were clearly visible in the 11C-SA4503 scans
(Fig. 1). The brains of animals with pituitary tumors also
appeared to take up more tracer than normal brain. The thyroid
glands were in the field of view, and they appeared to take up
more tracer in the tumor-bearing rats than in the normal aged rats
(Fig. 1).
Kinetics of Radioactivity in Plasma and Brain
Metabolite analysis revealed that about 50% of the parent tracer
remained intact at 60 min, but there was no significant difference
between the groups. The kinetics of radioactivity in the plasma
(metabolite-corrected, n 5 4 each) after a bolus injection of 11C-
SA4503 are shown in Figure 2A. Values from 4 normal rats and
1 rat with tumor were not included in this analysis because of
FIGURE 3. Kinetic modeling parameters of 11C-SA4503 in normal pituitary (n 5 8) and
pituitary tumor (n 5 5) (A) and in brain of normal (n 5 8) and tumor-bearing (n 5 5) rats (B),
and correlation of 11C-SA4503 kinetic parameters (VT, BPND, K1/k2) in thyroid and brain (C).
Data are expressed as mean 6 SEM and were tested with unpaired 2-tailed t test.
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nonavailability of plasma
samples (failure of the can-
nula and changed kinetics
due to a small depot during
tracer injection). Rapid
biexponential clearance was
observed in both groups.
The presence of the pituitary
tumor did not significantly
affect the plasma kinetics of
the tracer. The area under the
curve for normal rats was
18.0 6 3.1; that for rats with
tumor was 13.1 6 0.8, (P 5
0.1720).
The kinetics of 11C-
SA4503 in the pituitary and
pituitary tumor, the brain,
and the thyroid are pre-
sented in Figures 2B–2D.
Tracer uptake was rapid in
normal brain, normal pitui-
tary, and brain with tumor, with the peak appearing within
5 min of tracer injection, and was followed by a slow washout.
Uptake in the pituitary tumor, although also rapid, plateaued
within 10 min, and no appreciable washout was seen within the
scanning duration. Uptake of the tracer was significantly higher in
the tumor than in the normal pituitary and was about 3-fold
higher by the end of the scan (area under the curve, 439.6 6
104.4 vs. 166.6 6 8.6, P , 0.05). Uptake was also higher in the
tumor than in the brain of tumor-bearing rats and was about 2-fold
higher by the end of the scan. Uptake was about 50% higher in
the brain of tumor-bearing rats than in the brain of normal
aged rats.
Kinetic Analysis
Using the metabolite-corrected arterial plasma as input, we fitted
a 2-tissue-compartment model to regions of interest drawn around
whole brain, normal pituitary, pituitary tumor, and thyroid. When
plasma data were not available, a population average corrected for
injected dose andweight of individual animalwas used as input. The
VT (Fig. 3A) of the tracer was significantly higher (P , 0.05) in
tumor (105.0 6 47.6) than in the normal pituitary (11.6 6 1.0).
Furthermore, the VT was higher in the brain tissue of animals with
pituitary tumors than in the brain tissue of normal rats (25.563.3 vs.
11.86 1.2, P, 0.001) (Fig. 3B). Additionally, the VTwas higher in
the thyroid of rats with pituitary tumors than in the thyroid of normal
rats (39.3 6 5.5 vs. 23.16 1.9, P , 0.01).
The higher VT in the tumor was associated with a significantly
higher BPND (10.7 6 1.7 vs. 4.6 6 0.5, P , 0.01) and K1/k2
(10.5 6 4.5 vs. 2.2 6 0.3, P , 0.05) (Fig. 3A). On the other
hand, the higher VT in the brain was not related to a change in
BPND but was due to a higher partition coefficient (K1/k2) of 11C-
SA4503 (6.6 6 1.3 vs. 2.4 6 0.4, P , 0.01, (Fig. 3B). Similarly,
the higher VT in the thyroid was related to a higher K1/k2 (8.8 6
1.3 vs. 5.1 6 0.8, P , 0.05) rather than to BPND. Changes in VT
and K1/k2 in the brain and thyroid were strongly correlated (R2 5
0.81, P , 0.0001, and R2 5 0.85, P , 0.0001, respectively).
The correlation between changes in BPND was not as strong
but still quite significant (R2 5 0.66, P 5 0.0014) (Fig. 3C).
However, changes in K1/k2 in brain and pituitary or tumor corre-
lated only weakly (R2 5 0.38, P , 0.05), and changes in VT
and BPND were not correlated at all (R2 5 0.19, P 5 0.1372,
and R2 5 0.02, P 5 0.6622, respectively).
FIGURE 4. Ratio of s-1 receptor
protein to b-actin from Western
blotting in normal pituitary (n 5 5)
and pituitary tumors (n 5 5). Data
are expressed as mean 6 SEM
and were tested with unpaired 2-
tailed t test. Inset shows represen-
tative bands.
TABLE 2
Biodistribution of 11C-SA4503 in Brain and Peripheral Regions
SUV Tissue-to-plasma ratio
Tissue Normal aged (n 5 7) With tumor (n 5 5) P Normal aged (n 5 7) With tumor (n 5 5) P
Cerebellum 1.21 6 0.12 2.08 6 0.25 ,0.001 7.06 6 1.01 20.67 6 1.92 ,0.001
Cerebral cortex 1.55 6 0.05 2.31 6 0.16 ,0.01 8.97 6 0.79 23.30 6 2.13 ,0.001
Rest of brain 1.28 6 0.05 1.87 6 0.18 ,0.05 7.41 6 0.70 18.54 6 1.14 ,0.001
Adipose tissue 0.32 6 0.10 0.38 6 0.19 NS 1.91 6 0.65 3.59 6 1.74 NS
Bladder 3.09 6 1.29 2.28 6 0.93 NS 19.81 6 9.26 22.82 6 8.62 NS
Bone 0.43 6 0.08 0.62 6 0.08 NS 2.48 6 0.55 6.45 6 1.20 NS
Bone marrow 3.55 6 1.10 2.72 6 0.90 NS 18.77 6 5.09 27.10 6 8.72 NS
Heart 0.61 6 0.05 0.93 6 0.05 NS 3.49 6 0.37 9.43 6 1.00 NS
Large intestine 2.41 6 0.27 2.94 6 0.15 NS 14.30 6 2.35 30.74 6 5.18 NS
Small intestine 3.50 6 0.38 5.41 6 0.52 NS 20.26 6 3.07 55.59 6 8.43 ,0.01
Kidney 3.50 6 0.25 4.08 6 0.55 NS 20.40 6 2.34 41.62 6 6.77 NS
Liver 11.05 6 0.63 11.68 6 1.15 NS 63.83 6 5.83 115.42 6 6.67 ,0.001
Lung 2.21 6 0.14 3.85 6 0.60 NS 12.71 6 1.18 39.32 6 6.93 NS
Muscle 0.30 6 0.06 0.47 6 0.08 NS 1.70 6 0.32 4.83 6 0.92 NS
Pancreas 5.74 6 1.01 5.31 6 0.77 NS 33.23 6 6.82 55.07 6 10.28 NS
Plasma 0.18 6 0.01 0.10 6 0.01 NS 1.00 1.00 NS
Red blood cells 0.09 6 0.02 0.06 6 0.01 NS 0.50 6 0.10 0.64 6 0.06 NS
Spleen 4.10 6 0.29 5.77 6 0.77 NS 24.13 6 3.13 58.12 6 7.82 ,0.01
Submandibular gland 6.67 6 0.83 4.90 6 0.97 NS 37.24 6 3.93 53.76 6 16.45 NS
Urine 4.76 6 2.07 3.676 6 1.69 NS 31.26 6 14.76 40.07 6 18.42 NS
NS 5 not statistically significant.
Data are expressed as mean 6 SEM.
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Biodistribution
The mass of a normal pituitary was 12.76 3.3 mg (mean6 SD,
n 5 5; range, 8.6–17.7 mg). Spontaneous pituitary tumors
weighed 70.5 6 93.1 mg (mean 6 SD, n 5 8; range, 14.0–
274.7 mg). The biodistribution data of 11C-SA4503 90 min after
injection showed considerable uptake in the pituitary tumor (SUV,
10.3 6 2.1)—about 3-fold higher than in the normal pituitary
gland. The accumulation of 11C-SA4503 was about 100-fold
higher in tumor tissue than in plasma and about 6-fold higher than
in the adjacent brain (Table 1).
The biodistribution data for the brain areas and peripheral
organs are listed in Table 2. The presence of the pituitary tumor was
associated with a significantly higher SUV and tissue-to-plasma
ratio of the tracer in all brain areas. SUVs in the peripheral organs
of normal and tumor-bearing rats were not significantly different,
but tissue-to-plasma ratios in the brain, small intestine, liver, and
spleen of tumor-bearing animals were significantly higher.
Western Blotting
Western blotting was performed to quantify the s-1 receptor
proteins in the pituitary tumor and normal pituitary. Immunoreac-
tive bands for s-1 receptor proteins were visualized at 25 kDa. The
ratio ofs-1 receptor protein tob-actinwas significantly higher in the
pituitary tumors than in normal pituitary (1.94 6 0.21 vs. 0.97 6
0.13, P , 0.01) (Fig. 4).
DISCUSSION
This study demonstrated that spontaneous pituitary tumors in
aged rats can be detected and distinguished from normal pituitary
and brain by small-animal PET imaging with the s-1 ligand 11C-
SA4503. To the best of our knowledge, this is the first report
identifying s-1 receptors in pituitary tumors.
For clear visualization of tumor lesions, the ratio of tracer
uptake in tumor versus surrounding tissue must be ..1. In the
biodistribution experiments, we observed an accumulation of 11C-
SA4503 about 6-fold higher in the pituitary tumors than in
the adjacent brain and about 100-fold higher than in plasma. There-
fore, the pituitary tumors were easily visualized with 11C-SA4503.
Kinetic modeling indicated that VT in pituitary tumors increased
(by 10-fold), compared with the normal pituitary. These changes
in VT were related to increases in both K1/k2 and BPND (4.9-fold
and 2.3-fold, respectively). Tracer VT in the brain of pituitary
tumor–bearing rats was increased (by 2.4-fold), compared with
the brain of healthy rats, because of an increase in K1/k2 (by
2.7-fold), whereas BPND was unaltered (Fig. 3A). Since the pitu-
itary is adjacent to the brain, partial-volume effect could play a role
in the increased VT in the brains of rats with pituitary tumor.
However, the higher SUV in the brains of animals with pituitary
tumor in the biodistribution study suggests that this effect is in-
dependent of partial-volume effects. A 1.7-fold increase in K1/k2
(but not BPND) was also observed in the thyroid gland of tumor-
bearing rats (Fig. 3B).
Increases in the partition coefficient (K1/k2) of the tracer were
observed not only in pituitary tumors but also in the brain and
thyroid. Increases in K1/k2 are thus not limited to tumor tissue.
Pituitary tumors are known to exert global effects on blood flow
(32) and different effects on regional blood pressure (33). Altered
tissue-to-plasma ratios of 11C-SA4503 in the brain, small intestine,
liver, and spleen of tumor-bearing animals (Table 2) may be re-
lated to such phenomena, although additional data on hormone
levels and tissue perfusion are required to prove the underlying
mechanism.
A change in BPND could indicate a change in either receptor
numbers or affinity. If the affinity of 11C-SA4503 to s-1 receptors
remains constant during malignant transformation, as has been
reported for nonneural tumors (33), the observed increase in BPND
in tumor tissue should reflect an upregulation of s-1 receptors in
pituitary tumors. Such upregulation would be consistent with the
moderate (generally 2- to 3-fold) overexpression of s-1 receptors
in other tumor tissues (17,33,34). Our results from Western blot-
ting also confirmed a 2-fold overexpression of s-1 receptors in
pituitary tumors. The reason for upregulation of s-1 receptors in
tumor tissue is unclear, but the upregulation may provide the
tumor cells with an additional brake on apoptosis (35). Since
BPND values in the brain and thyroid of tumor-bearing rats were
not increased, s-1 receptor expression in these organs appears to
be unaffected by the pituitary tumor.
In this study, we did not find any correlation between BPND and
tumor size. Similarly, in a study on 95 breast cancer patients, no
correlation was observed between s-1 receptor levels and tumor
size, histologic grade, or expression of the proliferation marker,
Ki-67, although a positive correlation was reported between s-1
receptor levels, hormone receptor positivity (in particular proges-
terone receptor), Bcl-2 expression, and the period of disease-free
survival (36). Low ratios (,1) of prosurvival Bcl-2 and proapop-
totic Bax expression predominate in nonfunctioning pituitary
tumors and pituitary microadenomas (37).
CONCLUSION
The very high uptake of 11C-SA4503 in pituitary adenomas indi-
cates that testing of 11C-SA4503-PET in a clinical setting may be
worthwhile. The fact that even very small tumors were clearly
detected (lesion mass in Fig. 1 was 17 mg) suggests that 11C-
SA4503may be applied for the detection of microadenomas. Future
studies are needed to answer the question of whether 11C-SA4503-
PET can discriminate between symptomatic, hormone-secreting,
and nonfunctioning (nonsymptomatic, nonsecretive) tumors.
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